Related Experiment Video

Updated: Jun 22, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Antifibrosis: to reverse the irreversible

Ziv Paz1, Yehuda Shoenfeld

  • 1Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.

Clinical Reviews in Allergy & Immunology
|June 24, 2009
PubMed

Insights

Fibrosis involves scar formation and extracellular matrix overproduction, leading to life-threatening diseases. While considered irreversible, new drugs show promise in treating fibrotic conditions.

Area of Science:

  • Pathology and Molecular Biology
  • Connective Tissue Disorders
  • Immunology

Background:

  • Fibrosis is a pathological process characterized by scar formation and excessive extracellular matrix deposition.
  • It affects multiple organs, leading to progressive and life-threatening conditions.
  • Understanding the molecular mechanisms involving various cells, cytokines, and enzymes is crucial.

Purpose of the Study:

  • To review the current understanding of the molecular mechanisms underlying fibrotic diseases.
  • To explore the challenges in treating fibrosis and the limitations of current therapies.
  • To highlight emerging therapeutic strategies and drugs with potential antifibrotic effects.

Main Methods:

  • Literature review of scientific articles on fibrosis.
  • Analysis of molecular pathways and cellular components involved in fibrotic processes.
  • Evaluation of existing and novel therapeutic agents for fibrotic diseases.

Main Results:

  • Fibrosis is a complex process involving intricate molecular signaling.
  • Current treatments, primarily anti-inflammatory and immunosuppressive agents, have limited efficacy.
  • Several drugs, including mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin, show promising antifibrotic potential.

Conclusions:

  • Fibrotic diseases pose a significant clinical challenge due to their progressive nature and limited treatment options.
  • Advances in understanding fibrosis mechanisms have paved the way for developing targeted antifibrotic therapies.
  • Further research and clinical trials are essential to validate the efficacy of novel antifibrotic drugs.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...